EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
M. Tiseo, F. Gelsomino, D. Boggiani, B. Bortesi, M. Bartolotti, C. Bozzetti, G. Sammarelli, E. Thai, A. Ardizzoni
20110101
2011 Feb 1
Lung Cancer
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
Lung Cancer. 2011 Feb;71(2):241-243, M. Tiseo, F. Gelsomino, D. Boggiani, B. Bortesi, M. Bartolotti, C. Bozzetti, G. Sammarelli, E. Thai, A. Ardizzoni
The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small cell lung cancer (NSCLC). EML4-ALK translocations correlate with specific clinical and pathological features, in particular lack of EGFR and K-ras mutations, and may be associated with resistance to EGFR tyrosine-kinase inhibitors (TKIs). Here, we report a case of a patient with a concomitant EGFR mutation and ALK...
